| Zhang, Huilai |
Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury |
|
|
| Recruiting | 4 | 165 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention | The First Affiliated Hospital of Dalian Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anqing Municipal Hospital, Henan Cancer Hospital, Wuhan Union Hospital, China, Peking University Shougang Hospital, Chinese PLA General Hospital, Liaoning Tumor Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Henan Provincial People's Hospital, Shanxi Provincial Cancer Hospital, Beijing Sanhuan Cancer Hospital, Hebei Medical University Fourth Hospital, Tongji Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Bethune Charitable Foundation | Cancer Treatment Induced Thrombocytopenia | 06/24 | 08/24 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 2 | 29 | RoW | Orelabrutinib in in combination of rituximab and lenalidomide(OLR), OLR Arm | Tianjin Medical University Cancer Institute and Hospital | Mantle Cell Lymphoma | 10/22 | 10/23 | | |
NCT06149169: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma |
|
|
| Active, not recruiting | 2 | 10 | RoW | CD19-targeted Chimeric Antigen Receptor(CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | 10/24 | 03/25 | | |
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 77 | RoW | Orelabrutinib and Gemox, O-Gemox | Sun Yat-sen University | DLBCL | 12/23 | 12/25 | | |
NCT05590221: Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Peking University Cancer Hospital & Institute, Shanghai Ming Ju Biotechnology Co., Ltd. | B-cell Lymphoma | 02/24 | 12/24 | | |
NCT06433362: CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 115 | RoW | CMOEP | Tianjin Medical University Cancer Institute and Hospital | Peripheral T Cell Lymphoma | 06/25 | 06/26 | | |
| Recruiting | 2 | 12 | RoW | Relma-cel, CD19-targeted Chimeric Antigen Receptor(CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Non-Hodgkin Lymphoma, Large B-cell Lymphoma | 04/25 | 12/26 | | |
NCT06570447: Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL |
|
|
| Not yet recruiting | 2 | 22 | RoW | Glofitamab, Chidamide | Tianjin Medical University Cancer Institute and Hospital | Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory | 12/26 | 12/28 | | |
NCT06704555: Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | radiation therapy, Tiselizumab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | Tianjin Medical University Cancer Institute and Hospital | Follicular Lymphoma | 12/25 | 12/27 | | |
| Recruiting | 1/2 | 120 | RoW | Chidamide, HDACi, Fludarabine and cyclophosphamide, FC regimen, Anti-CD19 CAR-T cells, Relma-cel, Axi-cel, Other commercial CAR-T cells, Experimental CAR-T cells | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 06/24 | 06/25 | | |
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1a/1b | 30 | RoW | IBI397, IBI397+Sintilimab, IBI397+Rituximab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 08/23 | 08/23 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT06395870: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 33 | RoW | LUCAR-G39D cells product | Tianjin Medical University Cancer Institute and Hospital, Nanjing Legend Biotech Co. | B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory | 06/26 | 06/28 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Not yet recruiting | N/A | 1000 | RoW | Linperlisib, YY-20394 | Ruijin Hospital, Tianjin Medical University Cancer Institute and Hospital | Focus on the Lymphoma Including B/T-cell Lymphoma | 06/27 | 06/27 | | |
| Song, Yue |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT04782674: Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related Diseases |
|
|
| Recruiting | N/A | 40 | RoW | Saliva Testing | Beijing Friendship Hospital | EBV Infection | 04/22 | 04/22 | | |
PLACARD, NCT06336239: PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study |
|
|
| Recruiting | N/A | 3000 | RoW | | Beijing Anzhen Hospital | Cardiovascular Disease, Type 2 Diabetes Mellitus | 07/24 | 12/24 | | |
| Liu, Xiaohui |
NCT04078568: Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease |
|
|
| Active, not recruiting | 3 | 3208 | RoW | IVIG, Intravenous Immunoglobulins, Human, Aspirin, Acetylsalicylic acid, Prednisolone, STEROLONE | Children's Hospital of Fudan University, Jiangxi Province Children's Hospital, First People's Hospital of Hangzhou, Shengjing Hospital, The First Hospital of Jilin University, Chengdu Women's and Children's Central Hospital, Children's Hospital of Chongqing Medical University, Inner Mongolia People's Hospital, Sichuan Provincial People's Hospital, Wuhan Union Hospital, China, Third Affiliated Hospital of Zhengzhou University, Children's Hospital of Soochow University, Yuying Children's Hospital of Wenzhou Medical University, Beijing Children's Hospital, Qilu Hospital of Shandong University | Kawasaki Disease | 12/24 | 12/25 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
| Yu, Jingwei |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
